
QSV Biologics, Ltd. To Manufacture Synthetic Vitronectin for Tissue Therapies, Ltd.
QSV Biologics, Ltd. (Edmonton, Canada, www.qsvbiologics.com) has signed a contract with Tissue Therapies Limited (Brisbane, Australia, www.tissuetherapies.com) for the cGMP manufacture of clinical quantities of synthetic Vitronectin (a component of the wound-healing treatment VitroGro) and a single-protein chimeric form of VitroGro.
QSV Biologics, Ltd. (Edmonton, Canada,
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.